Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Owen Mumford Announces £14m Investment in New, State-of-the-Art, BREEAM-certified Premises

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, today announced that work has started on the build of a brand-new, state-of-the-art production facility in Witney, Oxfordshire, UK.

The new building is commissioned to align with the company’s strong sustainability agenda, designed in accordance with the latest environmental standards to obtain BREEAM certification, the world’s leading sustainability assessment for buildings. A ground-breaking ceremony took place to mark the commencement of building work, attended by the Chairman Mark Owen, son of one of the original founders, as well as CEO Jarl Severn.

The £14 million investment project will facilitate the organisation’s ongoing development of innovative medical devices through sustainable design and manufacturing methods. The design of the building will conform to BREEAM certification, which recognises the highest levels of environmental, social and economic sustainability performance, not only protecting natural resources but enhancing the well-being of associates who will be located there. During the planning phase, Owen Mumford has worked closely with ecologist specialists to ensure there has been no negative impact on biodiversity, and targets have been set to show biodiversity gains during and after construction. The latest technology and materials are being used to ensure the effective deployment of energy, heating and cooling.

Owen Mumford’s new Witney site will set a benchmark for world-class design and development in medical devices, establishing a centre of excellence for automation and assembly to deliver a portfolio that drives innovation and growth for the long term. It will also be the location for production of the company’s recently launched, next generation auto-injector Aidaptus®, the industry’s first single-use auto-injector for 1mL and 2.25mL pre-filled syringes as well as its pioneering springless safety syringe Unisafe® and the latest lancets for blood sampling.

“Since we first started to significantly ramp up our sustainability agenda in 2014, we have achieved many important milestones, and today’s ground-breaking ceremony at our new Witney site is a fitting tribute to the journey we are on,” said Jarl Severn, CEO at Owen Mumford. “We are setting the benchmark high for manufacturing to do its part in the overall reduction of environmental impact. Our investment in this new facility supports the promises we make to all our stakeholders by providing the very best platform for innovation in our products, but most importantly by doing it in a truly responsible and ethical way.”

Earlier this year, Owen Mumford achieved B Corp certification after demonstrating strict compliance to the rigorous requirements of the assessment – covering governance, community, workers, environment and customers.

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy